Ibandronic acid

From WikiProjectMed
Jump to navigation Jump to search
Ibandronic acid
Ibandronate.svg
Names
Trade namesBoniva, Bonviva, Bondronat, others
Other namesIbandronate sodium
Clinical data
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
use
By mouth, intravenous
External links
AHFS/Drugs.comMonograph
US NLMIbandronic acid
Legal
License data
Legal status
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetics
Bioavailability0.6%
Protein binding90.9 to 99.5%
(concentration-dependent)
MetabolismNil
Elimination half-life10 to 60 hours
ExcretionKidney
Chemical and physical data
FormulaC9H23NO7P2
Molar mass319.231 g·mol−1
3D model (JSmol)
  • O=P(O)(O)C(O)(CCN(CCCCC)C)P(=O)(O)O
  • InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17) checkY
  • Key:MPBVHIBUJCELCL-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ibandronic acid, also known as ibandronate, is a medication used treat of osteoporosis, high calcium due to cancer, and bone metastases from breast cancer.[1][2] It may be taken by mouth or injection into a vein.[1]

Common side effects include heart burn, low calcium, weakness, headache, and fever.[2] Other side effects may include anaphylaxis, esophagitis, femur fracture, and osteonecrosis of the jaw.[2][3] It is a bisphosphonate and works by stopping bone breakdown by cells known as osteoclasts.[1][2]

Ibandronic acid was patented in 1986 by Boehringer Mannheim and approved for medical use in 1996.[4] It is available as a generic medication.[1] In the United Kingdom a 150 mg pill cost the NHS about £4.50 as of 2021.[1] This amount in the United States is about 12 USD.[5]

Medical uses

Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women.[6] The basis for this approval was a trial of women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.

Ibandronate is efficacious for the prevention of metastasis-related bone fractures in multiple myeloma, breast cancer, and certain other cancers.[7]

Dosage

For osteoporosis it is take by mouth at a dose of 150 mg per month or by intravenous at a dose of 3 mg every 3 month.[1]

Side effects

In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain.[8] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. [9] The drug also has been associated with osteonecrosis of the jaw, relatively rare but serious condition.[10]

Pharmacology

Relative potency[11]
Bisphosphonate Relative potency
Etidronate 1
Tiludronate 10
Pamidronate 100
Alendronate 100-500
Ibandronate 500-1000
Risedronate 1000
Zoledronate 5000

Society and culture

Cost

This medication has a cost in the U.S. of $51 (USD) for 3 tablets (150 mg)[12]

Brand names

Ibandronic acid is marketed under the trade names Boniva in the USA, Bondronat in Europe, Bonviva in Asia, Bandrone in India, Ibandrix in Ecuador, Adronil in Pakistan, Bondrova in Bangladesh and Bonprove in Egypt.

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 769. ISBN 978-0857114105.
  2. 2.0 2.1 2.2 2.3 "Bondronat". Retrieved 24 November 2021.
  3. "Ibandronate Monograph for Professionals". Drugs.com. Retrieved 24 November 2021.
  4. Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 523. ISBN 9783527607495.
  5. "Ibandronate Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 24 November 2021.
  6. "boniva". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
  7. Sittig HB (2012). "Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate". Onkologie. 35 (6): 380–7. doi:10.1159/000338947. PMID 22722461. S2CID 8413102.
  8. "Information for Healthcare Professionals: Bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa)". U.S. Food and Drug Administration. Retrieved 27 October 2010.
  9. "Drugs Commonly Prescribed for Osteoporosis Patients are Effective at Reducing Risk of Hip and Spine Fractures, But Panel Says May be Related to Unusual Thigh Bone Fractures When Used Long Term". Journal of Bone and Mineral Research=27 October 2010.
  10. "Osteonecrosis of the jaw (ONJ) and drug treatments for osteoporosis" (PDF). nos.org.uk. The National Osteoporosis Society.
  11. Tripathi KD (2013-09-30). Essentials of medical pharmacology (Seventh ed.). New Delhi. ISBN 9789350259375. OCLC 868299888.
  12. "Ibandronate Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 1 April 2021.

External links

Identifiers: